FonesLife Corporation, a subsidiary of NEC Solution Innovators, Ltd. of Japan, announced today that they will begin offering blood-based health tests built on the SomaLogic SomaScan® Platform to consumers in Japan. The tests, which deliver health-management information based on large-scale measurements of an individual’s blood proteins, are expected to help assess health and promote wellness in Japan’s rapidly aging population.
SomaLogic, Inc., global leader in proteomic discovery and applications transforming biomedical discovery and clinical diagnostics, announced today that the Company has successfully closed an Initial Series A capital raise of $121 Million. The Company anticipates that additional closings will occur within the next 90 days.
SomaLogic, Inc. announced today an agreement with the US Food and Drug Administration (FDA)’s Division of Applied Regulatory Science to evaluate the utility of large-scale analysis of proteins (proteomics) for the identification of biomarkers that may be useful in demonstrating biosimilarity of a proposed biosimilar to a reference biologic.
SomaLogic, Inc. announced today that a collaborative project between SomaLogic scientists and academic researchers has received a $1 million dollar Phase 1 grant from the National Science Foundation Convergence Accelerator program. The team will apply recent advances in quantum sensing to improve methods for proteomic screening.
On December 5, 40 special mice were launched inside a Dragon capsule on a new Falcon 9 booster rocket from Cape Canaveral Air Force Station, headed toward the International Space Station for a 33-day mission. The SomaScan® Assay was used to measure proteomic changes in the mice after their spaceflight and revealed certain biochemical pathways that can be blocked to protect against both muscle and bone loss.
SomaLogic Announces New Agreement with Amgen to Accelerate Drug Discovery and Development Efforts through Comprehensive Proteomic Profiling
SomaLogic, Inc. announced today an agreement with Amgen that will use SomaLogic’s proprietary proteomics technology to help advance Amgen’s drug discovery and development programs. The agreement builds upon SomaLogic’s existing collaboration with deCODE genetics, an Amgen subsidiary based in Iceland, and will include broader application across Amgen’s pipeline.
SomaLogic, Inc. and NEC Solution Innovators, Ltd. of Japan, a subsidiary of NEC Corporation, announced today the establishment of FonesLife Corporation, a new Tokyo-based company that will bring a series of new clinical health management tests based on SomaLogic’s proprietary protein-measurement technology to the Japanese people.
At SomaLogic, we measure proteins in the human body, and derive important health insights from that information for each individual. Depending on the day, the expression of these proteins in each individual human body can vary significantly, and we analyze this variability to discern patterns that may predict current conditions or future disease. But however variable the expression may be, we also know that the identity of every individual’s proteins are the same, regardless of skin color, country of origin, gender, religious preference or socioeconomic status. We always measure these proteins the same way because we know there is only one species of human beings.
Today SomaLogic, Inc. announced an enhanced collaboration with NEC Solution Innovators, Ltd. of Japan, a subsidiary of NEC Corporation, that builds on the companies’ ten-year partnership by bringing new clinical tests based on SomaLogic’s proprietary protein-measurement technology to the Japanese population.
SomaLogic announced today that it has added a new set of four research use only (RUO) SomaSignal™ tests that can diagnose all four components of non-alcoholic steatohepatitis (NASH) without the need for an invasive liver biopsy.